Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [5][24] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89, up from $5.53 a year ago [5][24] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [6][24] - Adjusted EBITDA margin for Q4 was approximately 19.8%, down from 23% in the prior year [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and consumer healthcare core sales up by 3% [17][18] - Injectables core sales surged by 24%, driven by strong demand for elastomeric components [18] - Beauty segment core sales increased by 10%, with personal care core sales rising by 17% [19][20] - Closures segment core sales increased by 1%, with beverage core sales up by 7% [21] Market Data and Key Metrics Changes - Strong demand was noted in the pharma segment, particularly for systemic nasal drug delivery and injectables [4][8] - The beauty segment experienced double-digit growth across fragrance and facial skincare markets [4][19] - The closures segment saw volume growth, although impacted by lower resin pricing [21] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and back-office centralization through global talent centers [4][29] - There is an emphasis on productivity measures and efficiency improvements, with expectations for continued growth in the pharma segment excluding emergency medicine [30][28] - The company aims to maintain a disciplined approach to capital allocation while investing in long-term growth opportunities [6][25] Management's Comments on Operating Environment and Future Outlook - Management anticipates near-term headwinds in emergency medicine extending through 2026, with a revenue headwind of approximately $65 million expected [26] - The company expects steady improvements in beauty margins and overall performance in the second half of 2026 [34][39] - There is confidence in the growth potential of the pharma segment, particularly in injectables and systemic nasal drug delivery technologies [30][45] Other Important Information - The company returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends [6][25] - The company issued $600 million of senior notes in Q4 2025 to support its capital structure [23] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [32][33] Question: What is the expectation for EBITDA margin trends throughout the year? - Margins are expected to improve significantly in the second half of the year, driven by increased volume and productivity measures [34] Question: Can you elaborate on the margin performance in beauty and closures? - Operational issues and environmental upgrades impacted margins, but improvements are expected as these issues are resolved [39][40] Question: What is the outlook for emergency medicine sales? - Emergency medicine is expected to face challenges, with a significant decline anticipated in the first half of 2026 [26][41] Question: How does the company view the growth potential for Narcan and cough and cold products? - Management sees low to mid-single-digit growth for Narcan and anticipates a strong cough and cold season, with updates expected in Q1 and Q2 [46][48]

Financial Performance - The company achieved consolidated revenue of INR 8,805 crore ($992 million), reflecting a year-over-year growth of 9.8% and a sequential growth of 3% [4][5] - EBITDA margin for the quarter was reported at 26.7%, a decrease of 174 basis points year-over-year [8][10] - Profit after tax attributable to equity holders was INR 1,437 crore ($162 million), representing a 14% year-over-year growth [10][11] - The effective tax rate for the quarter was 22.2%, down from 30% in the same period last year [10] Business Line Performance - North America generics revenue declined by 16% year-over-year to $373 million, impacted by price erosion and lower Revlimid sales [19] - The European business reported revenue of €135 million, a growth of 150% year-over-year, driven by the acquired nicotine replacement therapy portfolio [20] - Emerging markets delivered revenue of INR 1,655 crore, reflecting a 14% year-over-year growth, supported by new product launches [20] - The India business reported revenues of INR 1,578 crore, achieving a 13% year-over-year growth, driven by new product launches and improved pricing [21] Market Performance - The North America generics market faced pressure from product-specific price erosion, particularly for lenalidomide [19] - The European market growth was primarily due to contributions from the nicotine replacement therapy portfolio and new product launches [20] - The emerging markets, particularly Russia, showed resilience with a 13% year-over-year growth in constant currency terms [20] Company Strategy and Industry Competition - The company is focusing on growing its base business, scaling its presence in consumer healthcare, and advancing innovative therapies and biosimilars [13][24] - Strategic collaborations and acquisitions are being pursued to enhance the innovation ecosystem and expand capabilities in emerging therapeutic areas [23][24] - The company aims to maintain a commitment to returning to 25% EBITDA margin in the next two years, despite challenges from Revlimid sales [44] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory across various markets, with a focus on innovation and strategic acquisitions [15][24] - The company is actively addressing regulatory challenges and is optimistic about upcoming product approvals, particularly for abatacept and semaglutide [30][32] - The management acknowledged the competitive landscape in Canada for semaglutide, anticipating multiple players in the market [72] Other Important Information - The company has a net cash surplus of INR 2,751 crore ($310 million) as of September 30, 2025 [11] - The company retained its MSCI ESG rating of A for the second consecutive year, indicating strong sustainability performance [18] Q&A Session Summary Question: Expectations for Revlimid sales in Q3 - Management indicated that some Revlimid sales are expected in Q3, but at a lower level than in Q2 [27] Question: US product pipeline and meaningful launches - The management acknowledged the challenges in the US product pipeline but highlighted ongoing focus on biosimilars and complex generics [28] Question: Legal status of semaglutide in India - The company is currently challenging patents in India, awaiting a decision from the Delhi High Court [34] Question: Confidence in abatacept and semaglutide approvals - Management expressed high confidence in the upcoming BLA submission for abatacept and ongoing progress for semaglutide [30][32] Question: Growth sustainability in ex-US markets - Management affirmed confidence in maintaining growth in ex-US markets, driven by new product launches and strategic acquisitions [52]